Zolmsolan: Your Complete Guide to Migraine Relief
This blog post provides information extracted directly from the patient information leaflet (PIL) for Zolmsolan. It is important to consult with a healthcare professional for personalized medical advice. Zolmsolan 5 mg 6 pcs.
Tradename:
Zolmsolan
Compound:
Each mouth-dissolving film contains:
Zolmitriptan 2.5 mg
Auxiliary components:
Polyvinyl alcohol, polyethylene glycol, starch, glycerol, sucrose, menthol oil, simethicone.
Properties:
Zolmitriptan is a selective agonist [a substance that initiates a physiological response when combined with a receptor] of 5HT1B / 1D receptors [serotonin receptors found in blood vessels and nerve endings], the stimulation of which leads to vasoconstriction [the constriction of blood vessels]. It has a high affinity [the degree to which a substance tends to combine with another] for recombinant human 5HT1B / 1D receptors and a moderate affinity for 5HT1A receptors. Zolmitriptan has no affinity and does not show significant pharmacological activity [relating to the effects of drugs] in relation to 5HT2-, 5HT3-, 5HT4-, adrenergic [relating to the effects of adrenaline or noradrenaline], histamine [a compound released by cells in response to injury and in allergic and inflammatory reactions, causing contraction of smooth muscle and dilation of capillaries], muscarinic [relating to the effects of acetylcholine at muscarinic receptors] and dopamine receptors [receptors in the brain that bind to dopamine].
Zolmitriptan administration to laboratory animals resulted in vasoconstriction in the carotid artery basin. In addition, the results of studies on laboratory animals indicate that zolmitriptan blocks the central and peripheral activity of the trigeminal nerve [a major nerve in the head involved in pain signaling] by inhibiting the release of the peptide associated with the calcitonin gene [a peptide that affects calcium levels and may play a role in migraine], vasoactive intestinal peptide [a peptide that affects blood vessel dilation and intestinal function] and substance P [a peptide involved in pain transmission].
In clinical studies, the effect of zolmitriptan on headache and other migraine symptoms (such as nausea, photophobia [sensitivity to light], phonophobia [sensitivity to sound]) was observed after 1 hour and increased in the period from 2 to 4 hours after taking the drug.
Zolmitriptan is equally effective for migraine with aura [sensory disturbances that precede a migraine], migraine without aura, and migraine associated with menstruation. Taking zolmitriptan during the aura did not prevent migraine headache, so the drug should be taken after the onset of a painful attack.
Indications:
Relief of migraine attacks with or without aura.
Method of administration and dosage:
Stick the film on the surface of the tongue with dry hands.
The recommended dose of the drug for relieving a migraine attack is 2.5 mg (1 film). It is recommended to take the drug as early as possible after the onset of the headache, but the drug is effective when taken later after the onset of the attack.
If migraine symptoms recur within 24 hours, you can take a second dose of the drug. Do not take a second dose earlier than 2 hours after taking the first dose. If there is no clinical response after taking the first dose, it is unlikely that the drug will be beneficial again during the same attack.
If the patient has not achieved a therapeutic effect [a beneficial result from treatment] after taking a dose of 2.5 mg, Zolmsolan at a dose of 5 mg can be used to relieve subsequent migraine attacks.
Do not take more than 2 doses of the drug per day. The total dose of zolmitriptan taken during the day should not exceed 10 mg.
Zolmsolan is not indicated for the prevention of migraines.
Contraindications:
- hypersensitivity to any components of the drug;
- hemiplegic [a migraine that causes temporary weakness on one side of the body], basilar [a rare type of migraine with aura that causes symptoms like vertigo and double vision] and ophthalmoplegic migraine [a rare type of migraine that causes weakness of the eye muscles];
- uncontrolled arterial hypertension [high blood pressure];
- cardiac ischemia [reduced blood flow to the heart];
- Coronary vasospasm [spasm of the coronary arteries] / Prinzmetal angina [a type of chest pain caused by spasm of the coronary arteries];
- Wolff-Parkinson-White syndrome [a heart condition that causes a rapid heartbeat] or arrhythmias [irregular heartbeats] associated with other additional pathways of impulse conduction;
- diseases of the peripheral arteries [diseases affecting blood flow in the arteries of the limbs];
- a history of cerebral circulation [blood flow in the brain] (including stroke [damage to the brain caused by interruption of blood supply] or transient ischemic attack [a "mini-stroke" caused by a temporary interruption of blood supply to the brain]);
- severe renal failure [severe kidney failure] (CC less than 15 ml / min) [creatinine clearance, a measure of kidney function];
- joint use with other agonists [a substance that initiates a physiological response when combined with a receptor] of serotonin 5HT1B / 1D-receptors (for example, sumatriptan, naratriptan), ergotamine [a medication used to treat migraines] or its derivatives (including metizergide [a medication used to prevent migraines]), as well as within 24 hours after their cancellation;
- joint use with MAO-A inhibitors [a type of antidepressant] and within 14 days after their cancellation;
- lactose intolerance [inability to digest lactose], lactase deficiency [lack of the enzyme lactase] or glucose-galactose malabsorption [a condition where the body cannot absorb glucose and galactose];
- period of pregnancy (safety of use has not been studied);
- Children up to 18 years old;
- elderly age over 65 years (efficacy and safety of use have not been studied).
Precautionary measures:
The drug can be used only in cases of clearly diagnosed migraine. Before prescribing zolmitriptan, as well as other agents for the relief of migraine, it is necessary to exclude other possible serious neurological diseases [diseases affecting the nervous system] in patients with previously undiagnosed migraine, as well as in patients with an established diagnosis of migraine in the presence of atypical symptoms. Zolmitriptan is not indicated for the treatment of hemiplegic, basilar and ophthalmoplegic migraines. In patients taking agonists [a substance that initiates a physiological response when combined with a receptor] of serotonin 5HT1B / 1D receptors, cerebrovascular accidents [stroke] were observed, incl. stroke. Migraine patients may be at risk of developing certain disorders of the cerebral circulation [blood flow in the brain].
Side effects:
From the nervous system: often – disturbances in sensitivity, dizziness, hyperesthesia [increased sensitivity to touch], paresthesia [tingling or numbness], drowsiness, a feeling of warmth or cold, vertigo [a sensation of spinning].
From the side of the cardiovascular system: often – a feeling of palpitations [a feeling of rapid or irregular heartbeat].
From the digestive system: often – abdominal pain; nausea, vomiting, dry mouth.
From the musculoskeletal system: often – muscle weakness, myalgia [muscle pain].
Storage method:
Store at a temperature not higher than 30 degrees.
Package:
The cardboard box contains 6 films dissolving in the mouth, paper instructions.
Zolmsolan 5 mg 6 Oro-Dispersible Films
Oro-Dispersible Films [films that dissolve in the mouth] Coated Tablets Contain Zolmitriptan 5 mg Anti-Migraine. Dose: Initial Dose: Note: Administer At The Onset Of Migraine Headache One Tablet 2.5 mg (Maximum Single Dose:Two Tablets 5 mg) Second Dose May Repeat In 2 Hours If The Migraine Headache Has Not Resolved Or Returns After Transient Improvement. Maximum Daily Dose Two Tablets 10 mg. Contraindications [conditions or factors that serve as a reason to withhold a certain medical treatment] In Case Of Angina Pectoris [chest pain caused by reduced blood flow to the heart] History Of Myocardial Infarction [heart attack] Uncontrolled Hypertension [high blood pressure] Other Cardiovascular Disease [diseases of the heart and blood vessels] Or Ergotamine-Containing Medication [medications that contain ergotamine, used to treat migraines] Or Pregnancy.
طريقة الاستعمال (Method of Use - Arabic):
خذ فيلمًا واحدًا (5 مليجرام) في أول علامة على صداع الصداع النصفي. [Take one film (5 milligrams) at the first sign of a migraine headache.]
إذا لم يتحسن الصداع بعد ساعتين ، فيمكنك أن تأخذ فيلمًا ثانيًا (5 مليجرام). [If the headache does not improve after two hours, you can take a second film (5 milligrams).]
لا تأخذ أكثر من فيلمين (10 مليجرام) في أي فترة 24 ساعة. [Do not take more than two films (10 milligrams) in any 24-hour period.]
حجم العبوة (Package Size - Arabic):
6 أفلام [6 films]
المادة الفعالة (Active Ingredient - Arabic):
Zolmitriptan 5 مليجرام لكل فيلم [Zolmitriptan 5 milligrams per film]
الجرعة (Dosage - Arabic):
5 مليجرام عن طريق الفم ، حسب الحاجة لتخفيف الصداع النصفي الحاد. [5 milligrams by mouth, as needed to relieve acute migraine headache.]
قد تؤخذ جرعة ثانية من 5 مليجرام بعد ساعتين إذا كانت الجرعة الأولى غير فعالة. [A second dose of 5 milligrams may be taken after two hours if the first dose is ineffective.]
يجب ألا يتجاوز إجمالي الجرعة اليومية 10 مليجرام. [The total daily dose should not exceed 10 milligrams.]
طريقة العمل (Mechanism of Action - Arabic):
Zolmitriptan هو ناهض مستقبل السيروتونين 1B/1D انتقائي. [Zolmitriptan is a selective serotonin 1B/1D receptor agonist.] يُعتقد أنه يعمل عن طريق تضييق الأوعية الدموية المتوسعة في الرأس ومن خلال منع إطلاق المواد المنتجة للألم. [It is believed to work by constricting dilated blood vessels in the head and by preventing the release of pain-producing substances.]
معلومات إضافية (Additional Information - Arabic):
لا ينبغي استخدام Zolmitriptan لمنع صداع الصداع النصفي. [Zolmitriptan should not be used to prevent migraine headaches.]
لا ينبغي استخدام Zolmitriptan في الصداع العنقودي. [Zolmitriptan should not be used for cluster headaches.]
لا ينبغي استخدام الزوليتريبان من قبل الأشخاص الذين يعانون من مرض الشريان التاجي ، أو ارتفاع ضغط الدم غير المنضبط ، أو السكتة الدماغية. [Zolmitriptan should not be used by people with coronary artery disease, uncontrolled high blood pressure, or stroke.]
لا ينبغي استخدام Zolmitriptan من قبل الأشخاص الذين يتناولون بعض الأدوية ، مثل مشتقات الإرغوتامين ، ومثبطات MAO ، أو SSRIs. [Zolmitriptan should not be used by people taking certain medications, such as ergotamine derivatives, MAO inhibitors, or SSRIs.]
التحذيرات والآثار الجانبية (Warnings and Side Effects - Arabic):
يمكن أن يسبب Zolmitriptan آثارًا جانبية خطيرة ، مثل ألم الصدر ، وضيق التنفس ، والنوبات. [Zolmitriptan can cause serious side effects, such as chest pain, shortness of breath, and seizures.] إذا واجهت أيًا من هذه الآثار الجانبية ، فابحث عن الاهتمام الطبي على الفور. [If you experience any of these side effects, seek medical attention immediately.]
الآثار الجانبية الشائعة الأخرى من Zolmitriptan تشمل الدوخة والنعاس والتعب والغثيان. [Other common side effects of Zolmitriptan include dizziness, drowsiness, fatigue, and nausea.]
يخزن (Storage - Arabic):
يخزن Zolmitriptan في درجة حرارة الغرفة ، بعيدا عن الضوء والرطوبة. [Zolmitriptan should be stored at room temperature, away from light and moisture.]
Latest Information:
This information is based on the latest available data from the patient information leaflet. However, always consult with your doctor or pharmacist for the most up-to-date information and personalized medical advice.
Conclusion:
This blog post summarizes information about Zolmsolan from the patient information leaflet. Always consult a healthcare professional for medical advice and carefully read the leaflet provided with the medication.
About the Author
Dr. Ahmad Baker, PharmD
He is a senior pharmacist and health educator with extensive experience in the Middle East and North Africa region. Through his writing, Dr. Ahmad aims to empower communities by providing reliable, evidence-based health information. With expertise in clinical pharmacy and regulatory affairs, he strives to offer unique insights into healthcare and simplify complex medical concepts, making them accessible to everyone.
Legal Disclaimer
The information provided in this blog is for educational purposes only and is not a substitute for professional medical advice. We do not guarantee the accuracy or completeness of information regarding medications or medical products, and official sources should be verified before making any decisions. By using this blog, you agree to assume personal responsibility for relying on the information provided.
Comments
Post a Comment